In the future, after predicting the response by liquid biopsy etc., we will select an appropriate ICI, and use it in combination with a molecular target drug such as a VEGF (vascular endothelial growth factor) inhibitor, or anti-PD-L1, which has already been approved for other cancers such as melanoma. This evidence concerns the gene VEGFA and melanoma.